GlobeNewsWire
02 Jul 2026, 08:30 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
China's NMPA has granted conditional approval for ORPATHYS (savolitinib) to treat MET-amplified advanced gastric or gastroesophageal junction adenocarcinoma. — Regulatory approval for a new indication creates a direct path to revenue growth and expands the addressable patient population for HUTCHMED and AstraZeneca.
+0.60ORPATHYS is the first selective MET inhibitor approved in China for this specific patient population. — First-mover advantage in a specialized oncology niche typically allows for better market penetration and pricing power.
+0.40The estimated annual incidence of MET-amplification gastric cancer in China is approximately 18,000 patients. — Provides a quantifiable target market size to help investors estimate the potential commercial scale of the approval.
+0.20Continue reading
6 related stories
Top 1 mover · tap to explore
Pivotal Phase II study data showed an objective response rate (ORR) of 32.3% and a disease control rate (DCR) of 63.1%. — Clinical efficacy data supports the likelihood of physician adoption and successful commercialization.
+0.20Which stocks this story touches
The company received NMPA approval for ORPATHYS for the treatment of gastric cancer in China.
As the joint developer and commercial partner, the approval expands the clinical application and market potential of their product.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
10h ago
